← Back to Clinical Trials
Recruiting NCT06092814

NCT06092814 tACS to Enhance Language Abilities

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06092814
Status Recruiting
Phase
Sponsor University of Pennsylvania
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2024-07-12
Primary Completion 2028-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Active transcranial alternating current stimulation (tACS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2024-07-12 with a primary completion date of 2028-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to see if transcranial alternating current stimulation (tACS) can be used to enhance language abilities in people with post-stroke aphasia. Participants will receive real and sham tACS in conjunction with various language tests. Researchers will compare the post-stroke aphasia group with aged matched controls to see if brain response to tACS differs between groups.

Eligibility Criteria

Inclusion Criteria for Persons with Aphasia: 1. Presence of aphasia 2. Suffered a single, left hemisphere stroke 3. Stroke ≥6 months old (chronic) at the time of enrollment Inclusion Criteria for Healthy Controls: 1. Right-handedness 2. Must be able to understand the nature of the study, and give informed consent Exclusion criteria for Persons with Aphasia: 1. Inability to understand the nature of the study 2. Marked naming impairment 3. Impaired non-verbal, conceptual processing 4. History of significant medical or neurological disorder (other than stroke) 5. History of significant or poorly controlled psychiatric disorders 6. Current abuse of alcohol or drugs, prescription or otherwise 7. Nursing a child, pregnancy, or intent to become pregnant during the study 8. Clinically significant hearing loss 9. Contraindications to tACS 10. Contraindications to MRI Exclusion Criteria for Healthy Controls 1. Diagnosis of a neurodegenerative disease or clinically significant cognitive complaint 2. Any unrelated neurologic or physical condition that impairs communication ability 3. History of unrelated neurological conditions including but not limited to traumatic brain injury, stroke, or small vessel disease that has resulted in a neurologic deficit 4. Any additional neurological condition that would likely reduce the safety of study participation, including central nervous system (CNS) vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis or arteriovenous malformations 5. A medically unstable cardiopulmonary or metabolic disorder 6. Terminal illness associated with survival \<12 months 7. Major active psychiatric illness that may interfere with required study procedures or treatments as determined by the enrolling physician 8. Current abuse of alcohol or drugs, prescription or otherwise 9. Contraindications to tACS 10. Contraindications to MRI

Contact & Investigator

Central Contact

Daniela Sacchetti, MS

✉ danielas@pennmedicine.upenn.edu

📞 215 573 4336

Frequently Asked Questions

Who can join the NCT06092814 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06092814 currently recruiting?

Yes, NCT06092814 is actively recruiting participants. Contact the research team at danielas@pennmedicine.upenn.edu for enrollment information.

Where is the NCT06092814 trial being conducted?

This trial is being conducted at Philadelphia, United States.

Who is sponsoring the NCT06092814 clinical trial?

NCT06092814 is sponsored by University of Pennsylvania. The trial plans to enroll 120 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology